| Price Range 12mo avg: | $2M – $2.5M |
|---|---|
| $/sf 12mo avg: | $318.75 |
| CAP Rate 12mo avg: | 7.29% |
| NOI average: | $173,700 |
| Lease Terms: | 15yrs NNN |
| Building Size avg: | 7,500 SF |
| Lot Size avg: | 2.5+/- acres |
Fresenius is a global health care group with products and services for dialysis, the hospital and the medical care of patients at home.
The Fresenius Group consists of the following four business segments that are responsible for their own business operations worldwide: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed.
Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS)
Fresenius Medical Care is the world’s largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.7 million individuals worldwide. Through its network of 3,361 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatments for 286,312 patients around the globe. Fresenius Medical Care is also the world’s leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.
| S&P Credit Rating: | BBB- |
|---|---|
| Moody’s Credit Rating: | Ba1 |
| Annual Revenue 2014: | $15.8B |
| Annual Revenue 2013: | $14.6B |
| Revenue Growth: | ↑ 8% from 2013 |
| Net Income | $1.05B |
| Units (Dec. 2014) | 3,361 |
| Average Units Volume: | $4.7M |
Yahoo! Finance: FMS News Latest Financial News for FMS
-
Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y
on February 21, 2020 at 2:44 pm
Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong segmental performance and solid 2020 EPS outlook. […]
-
FMC sees U.S. government easing home dialysis goals
on February 20, 2020 at 4:53 pm
Fresenius Medical Care (FMC) , the world's largest kidney dialysis provider, is confident the U.S. government will soften initial targets for treating patients with kidney disease at home rather than in dedicated centres. Chief Executive Rice Powell told Reuters a goal laid out by the U.S. Department of Health and Human Services (HHS) last July for 80% of new patients to undergo dialysis at home or receive organ transplants by 2025 was under review amid industry criticism. While Fresenius is developing less bulky and easier-to-use dialysis equipment and smartphone apps for home treatment, Powell said dialysis companies risked financial penalties if they kept patients who were deemed unsuitable for home treatment in dialysis centres under the new goals. […]
-
Fresenius Medical says fourth-quarter operating profit up 3%
on February 19, 2020 at 8:21 pm
Germany's Fresenius Medical Care on Wednesday said quarterly adjusted operating income edged 3% higher as growth in dialysis services and products was partly offset by a negative adjustment for accounts receivable in a legal dispute in North America. The kidney dialysis provider, controlled by diversified healthcare group Fresenius SE , reaffirmed a guidance for 2020 revenue and net income to grow at a mid- to high single-digit rate in 2020, when measured without currency swings and excluding special items. Asia accounted for 11% of its total quarterly revenue of 4.58 billion euros. […]
-
A Trio of Stocks Set to Post Large Returns
on February 9, 2020 at 11:53 pm
They are reasonably priced and their earnings are expected to grow significantly Continue reading... […]
-
Why Fresenius Medical Care AG & Co. KGaA’s (ETR:FME) Return On Capital Employed Is Impressive
on January 27, 2020 at 9:42 am
Today we'll look at Fresenius Medical Care AG & Co. KGaA (ETR:FME) and reflect on its potential as an investment. To... […]
NYSE: FMS
